Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jun 2021
Price :
$35
*
At a glance
- Drugs Ecallantide (Primary)
- Indications Hereditary angioedema
- Focus Registrational; Therapeutic Use
- Acronyms EDEMA4
- Sponsors Dyax
- 05 Jun 2014 New trial record